Stakeholders Expect Flurry Of Compounding Action, Hope For Policy Fixes

Compounding experts do not expect FDA to let up on the gas in 2018 on implementing the Drug Quality and Security Act, but many experts hope the agency will rethink what some see as its initial missteps in implementing the compounding law, including a perceived overly lax bar for compounding bulk substances and copies of FDA-approved drugs. FDA is facing pressure on both sides of the compounding debate -- with those who want FDA to take a harder line like...